Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
Real-World Findings Support Long-Term Benefits of Continuous Treatment with LEQEMBI and Provide Important Insights into Treatment Experience Outside of a Clinical Trial Setting TOKYO and CAMBRIDGE, Ma
Biogen's Alzheimer's drug lowers toxic protein, but results were mixed
09:18am, Tuesday, 14'th Jul 2026
The lowest dose of Biogen's anti-tau Alzheimer's drug diranersen, which missed its primary goal in a midstage trial, reduced cognitive decline in five of six Alzheimer's assessment tools and signif
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared data from the Phase 2 CELIA study evaluating diranersen, an investigation
Can Biogen Score Another Win In Alzheimer's Disease?
09:15am, Tuesday, 14'th Jul 2026
Biogen and Ionis said Tuesday their tau-targeting Alzheimer's treatment slowed cognitive decline by 26% over the course of 18 months.
CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced data from the Phase 2 CELIA study evaluating diranersen, an investigational antisense oligonucleotide (AS
FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
05:36pm, Monday, 13'th Jul 2026
LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosing for initiation and maintenance (approved in the U.S.) U.S. launch of LEQEMBI IQLIK as an initiation dose
FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug
03:02pm, Monday, 13'th Jul 2026
The U.S. FDA on Monday approved an at-home starting dose of Eisai's and Biogen's Alzheimer's drug, allowing some patients to begin therapy with injections administered by themselves or a caregiv
Stock Market Today, July 13: Energy Stocks Cushion Dow as Tech Slides on Geopolitical Tensions
12:14pm, Monday, 13'th Jul 2026
Energy names help cushion the Dow as oil jumps on U.S.-Iran tensions and investors brace for key earnings and inflation data, today, July 13, 2026.
Biogen Stock Is Upgraded to Buy Ahead of Key Alzheimer's Drug Study Details
08:15am, Monday, 13'th Jul 2026
Biogen stock receives a bullish upgrade based on expectations the market will cheer the company's detailed data on its experimental Alzheimer's drug.
Futures are trading lower as we get ready for the start of second-quarter earnings this week, after a solid winning week on Wall Street.
This Biogen Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
07:07am, Monday, 13'th Jul 2026
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag
LEQEMBIÂ Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented
New clinical and real-world data support a subcutaneous treatment pathway from initiation through maintenance treatment, offering dosing convenience for patients and care partners TOKYO and CAMBRIDGE,
Why Biogen (BIIB) is Poised to Beat Earnings Estimates Again
01:11pm, Tuesday, 07'th Jul 2026
Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors.
04:02am, Saturday, 04'th Jul 2026
Biogen struggled in recent years after a major blockbuster lost exclusivity. The company's new focus on growth is bearing fruit -- and the latest acquisition strengthens Biogen's position in the key a
